Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: bacterial translocase inhibitors - Sankyo/Sequella

Drug Profile

Research programme: bacterial translocase inhibitors - Sankyo/Sequella

Alternative Names: SQ641; SQ922

Latest Information Update: 05 Feb 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Daiichi Sankyo Company
  • Developer Sequella
  • Class Aminoglycosides; Anti-inflammatories; Antibacterials; Nucleosides
  • Mechanism of Action Phospho-N-acetylmuramoyl pentapeptide transferase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Clostridium difficile infections; Crohn's disease
  • Discontinued Nontuberculous mycobacterium infections

Most Recent Events

  • 05 Feb 2018 SQ 641 is still in preclinical development for Crohn's disease in USA
  • 05 Feb 2018 Discontinued - Preclinical for nontuberculous Mycobacterium infections in USA (unspecified route)
  • 05 Feb 2018 Preclinical trials in Clostridium difficile infections in USA (unspecified route) (Sequella pipeline, February 2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top